Quality of life (QOL) for patients treated with FOLFOX+/-cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147
- Citation:
- J Clin Oncol vol 29 (suppl) abstr 3541
- Meeting Instance:
- ASCO 2011
- Year:
- 2011
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Parents:
- None
- Children:
- 2594
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- M. R. Mahoney J. A. Sloan J. M. Hubbard H. Liu A. F. Shields E. Chan R. M. Goldberg S. Gill M. S. Kahlenberg S. G. Nair D. J. Sargent S. R. Alberts
- Networks:
- Study
- NCCTG-N0147
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: